Clinical Trial Update: Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ADL5945 for opioid-induced constipation in adults on chronic opioid therapy; trial completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Constipation

Drugs mentioned

• ADL5945 (ADL5945)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Constipation | Phase 2 | Status: COMPLETED | Results posted: 2015-06-08